WO2017048857A3 - Methods of diagnosis and detection for steroidal drugs - Google Patents

Methods of diagnosis and detection for steroidal drugs Download PDF

Info

Publication number
WO2017048857A3
WO2017048857A3 PCT/US2016/051756 US2016051756W WO2017048857A3 WO 2017048857 A3 WO2017048857 A3 WO 2017048857A3 US 2016051756 W US2016051756 W US 2016051756W WO 2017048857 A3 WO2017048857 A3 WO 2017048857A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosis
detection
steroidal drugs
markers
Prior art date
Application number
PCT/US2016/051756
Other languages
French (fr)
Other versions
WO2017048857A2 (en
Inventor
Yetrib Hathout
Kristy Brown
Kanneboyina Nagaraju
Eric Hoffman
Original Assignee
Children's National Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's National Medical Center filed Critical Children's National Medical Center
Publication of WO2017048857A2 publication Critical patent/WO2017048857A2/en
Publication of WO2017048857A3 publication Critical patent/WO2017048857A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the discovery of a number of proteins identified as markers of efficacy and safety of corticosteroid-responsive treatments, including methods of using said markers.
PCT/US2016/051756 2015-09-14 2016-09-14 Methods of diagnosis and detection for steroidal drugs WO2017048857A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562218213P 2015-09-14 2015-09-14
US62/218,213 2015-09-14

Publications (2)

Publication Number Publication Date
WO2017048857A2 WO2017048857A2 (en) 2017-03-23
WO2017048857A3 true WO2017048857A3 (en) 2017-05-04

Family

ID=58289818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/051756 WO2017048857A2 (en) 2015-09-14 2016-09-14 Methods of diagnosis and detection for steroidal drugs

Country Status (1)

Country Link
WO (1) WO2017048857A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US20120264645A1 (en) * 2002-11-15 2012-10-18 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US20120264645A1 (en) * 2002-11-15 2012-10-18 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HATHOUT ET AL.: "Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.", PROC NAT ACAD SCI, vol. 112, no. 23, 9 June 2015 (2015-06-09), pages 7153 - 7158, XP055379927 *
PRANZATELLI ET AL.: "CCR4 agonists CCL22 and CCL17 are elevated in pediatric OMS sera: rapid and selective down-regulation of CCL22 by ACTH or corticosteroids.", J CLIN IMMUNOL, vol. 33, no. 4, May 2013 (2013-05-01), pages 817 - 825, XP055379922 *
VAN DE GARDE ET AL.: "Chronic exposure to glucocorticoids shapes gene expression and modulates innate and adaptive activation pathways in macrophages with distinct changes in leukocyte attraction.", J IMMUNOL, vol. 192, no. 3, 1 February 2014 (2014-02-01), pages 1196 - 1208, XP055379925 *

Also Published As

Publication number Publication date
WO2017048857A2 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
EP3546457A4 (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
WO2016149710A8 (en) Hiv-1 neutralizing antibodies and uses thereof
EP3405896A4 (en) Systems and methods for improving disease diagnosis
WO2016011222A3 (en) Circular polynucleotides
EP3484504A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3486242A4 (en) Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
EP3518806A4 (en) Arrhythmia diagnostic and/or therapy delivery methods and devices, and robotic systems for other uses
WO2015006555A3 (en) Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
WO2017077085A3 (en) Immunomodulatory antibodies
WO2016011306A3 (en) Terminal modifications of polynucleotides
EP3154594A4 (en) Fap-activated therapeutic agents, and uses related thereto
EP3510922A4 (en) Biosignal detection garment
EP3491026A4 (en) Human antibodies, pharmaceutical compositions and methods
IL252418A0 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
EP3451908A4 (en) Devices and methods for vascular navigation, assessment and/or diagnosis
EP3275867A4 (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
WO2014153030A3 (en) Methods of treating cancer and preventing cancer drug resistance
WO2015164392A8 (en) Novel anti-rnf43 antibodies and methods of use
EP3100731A4 (en) Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof
EP3334719A4 (en) Substituted benzimidazoles, their preparation and their use as pharmaceuticals
EP3344325A4 (en) Local administration of drugs for the treatment of asthma
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
EP3634228A4 (en) Systems and methods for visualizing clinical trial site performance
EP3449924A4 (en) Composition, crocins active site, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16847240

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16847240

Country of ref document: EP

Kind code of ref document: A2